(E)-N-[(4-methoxyphenyl)methoxy]pent-2-en-4-ynamide | 1312592-14-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (E)-N-[(4-methoxyphenyl)methoxy]pent-2-en-4-ynamide
• CAS: 1312592-14-5
• 化学式: C₁₃H₁₃NO₃
• 分子量: 231.251
• InChiKey: BDLFJSPGFMJKQL-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-phenylpropyl azide 、 (E)-N-[(4-methoxyphenyl)methoxy]pent-2-en-4-ynamide 在 triethylphosphite copper(I) iodide complex 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 以186 mg的产率得到(E)-N-(4-methoxybenzyloxy)-3-(1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl)acrylamide
  参考文献：
  名称：

  Histone Deacetylase Inhibitors through Click Chemistry

  摘要：

  Histone deacetylase inhibitors (HDACi) are a relatively new class of chemotherapy agents. Herein, we report a click-chemistry based approach to the synthesis of HDACi. Fourteen agents were synthesized from the combination of two alkyne and seven azido precursors. The inhibition of HDAC1 and HDAC8 was then determined by in vitro enzymatic assays, after which the cytotoxicity was evaluated in the NCI human cancer cell line screen. A lead compound 5g (NSC746457) was discovered that inhibited HDAC1 at an IC50 value of 104 +/- 30 nM and proved quite potent in the cancer cell line screen with GI(50) values ranging from 3.92 mu M to 10 nM. Thus, this click HDACi design has provided a new chemical scaffold that has not only revealed a lead compound, but one which is easily amendable to further structural modifications given the modular nature of this approach.

  DOI：

  10.1021/jm8005355
• 作为产物：
  描述：

  (2-methoxyethoxy)methyl (2E)-5-(trimethylsilyl)pent-2-en-4-ynoate 在 盐酸 、 草酰氯 、 N,N-二甲基甲酰胺 、 cesium fluoride 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 (E)-N-[(4-methoxyphenyl)methoxy]pent-2-en-4-ynamide
  参考文献：
  名称：

  基于点击的组蛋白脱乙酰基酶抑制剂的基于结构的优化

  摘要：

  以前，我们报道了一种基于点击化学的方法来合成一类新型的组蛋白脱乙酰基酶（HDAC）抑制剂[1]。发现前导化合物NSC746457与SAHA（伏立诺他州）一样有效。本文描述了通过使用HDAC2-TSA晶体结构对NSC746457进行的进一步优化。将NSC746457对接至HDAC2结合域表明，可以利用帽基结合基序侧翼的疏水残基Phe210进行结构优化。肉桂酸帽区​​域的亚甲基取代导致鉴定出更有效的HDAC抑制剂：异丙基衍生物5和叔丁基衍生物6，其IC 50值分别为22 nM和18 nM。

  DOI：

  10.1016/j.ejmech.2011.04.027

文献信息

• A sub-milligram-synthesis protocol for in vitro screening of HDAC11 inhibitors
  作者：Yinping Tian、Jin Jin、Congying Wang、Wenhui Lv、Xuewei Li、Xiaona Che、Yanchao Gong、Yanjun Li、Quanli Li、Jingli Hou、Peng G. Wang、Jie Shen

  DOI：10.1016/j.bmcl.2016.03.116

  日期：2016.5

  This work demonstrated the high efficiency of a sub-milligram-synthesis based medicinal chemistry method. Totally 72 compounds, consisting a tri-substituted pyrrolidine core, were prepared. Around 0.1 mg of each compound was solid-phase synthesized. Based on the additive property of UV absorptions of unconjugated chromophores of a molecule, these compounds were quantified by UV measurement. A hit, whose IC50 value was 1.2 mu M in HDAC11 inhibition assays, highlights the applicability of the approach reported here in future optimization works. (C) 2016 Published by Elsevier Ltd.
• Design and synthesis of O-GlcNAcase inhibitors via ‘click chemistry’ and biological evaluations
  作者：Tiehai Li、Lina Guo、Yan Zhang、Jiajia Wang、Zhonghua Li、Lin Lin、Zhenxing Zhang、Lei Li、Jianping Lin、Wei Zhao、Jing Li、Peng George Wang

  DOI：10.1016/j.carres.2011.03.026

  日期：2011.7

  Protein O-GlcNAcylation has been shown to play an important role in a number of biological processes, including regulation of the cell cycle, DNA transcription and translation, signal transduction, and protein degradation. O-GlcNAcase (OGA) is responsible for the removal of O-linked beta-N-acetylglucosamine (O-GlcNAc) from serine or threonine residues, and thus plays a key role in O-GlcNAc metabolism. Potent OGA inhibitors are useful tools for studying the cellular processes of O-GlcNAc, and may be developed as drugs for the treatment neurodegenerative diseases. In this study, Cu(I)-catalyzed 'Click' cycloaddition reactions between glycosyl azides and alkynes were exploited to generate inhibitory candidates of OGA. Enzymatic kinetic screening revealed that compound 7 was a potent competitive inhibitor of human O-GlcNAcase (K(i) = 185.6 mu M). Molecular docking simulations of compound 7 into CpOGA (Clostridium perfringens OGA) suggested that strong pi-pi stacking interaction between the compound and W490 considerably contributed to improving the inhibitory activity. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.
• Discovery and Extensive <i>in Vitro</i> Evaluations of NK-HDAC-1: A Chiral Histone Deacetylase Inhibitor as a Promising Lead
  作者：Jingli Hou、Zhonghua Li、Qinghong Fang、Congran Feng、Hanwen Zhang、Weikang Guo、Huihui Wang、Guoxian Gu、Yinping Tian、Pi Liu、Ruihua Liu、Jianping Lin、Yi-kang Shi、Zheng Yin、Jie Shen、Peng George Wang

  DOI：10.1021/jm201496g

  日期：2012.4.12

  Herein, further SAR studies of lead compound NSC746457 (Shen, J.; Woodward, R.; Kedenburg, J. P.; Liu, X. W.; Chen, M.; Fang, L. Y.; Sun; D. X.; Wang. P. G. J. Med. Chem. 2008, SI, 7417-7427) were performed, including the replacement of the trans-styryl moiety with a 2-substituted benzo-hetero aromatic ring and the introduction of a substituent onto the central methylene carbon. A promising chiral lead, S-(E)-3-(1-(1-(benzo[d]oxazol-2-yl)-2-methylpropyl)-1H-1,2,3-triazol-4-yl)-N-hydroxyacrylamide (12, NK-HDAC-1), was discovered and showed about 1 order of magnitude more potency than SAHA in both enzymatic and cellular assays. For the in vitro safety tests, NK-HDAC-1 was far less toxic to nontransformed cells than tumor cells and showed no significant inhibition activity against CYP-3A4. The pharmaceutical properties (LogD, solubility, liver micrsomal stability (t1/2), plasma stability (t1/2), and apparent permeability) strongly suggested that NK-HDAC-1 might be superior to SAHA in bioavailability and in vivo half-life.